One of our premier internal research projects involves the development of novel, selective inhibitors of Janus kinase 3, a compound class of great potential for the treatment of inflammatory diseases. We recently demonstrated methods to optimize the compound class’ pharmacokinetic properties in order to obtain potent and stable drugs for in vivo use. One of the described methods involves conjugation with a carrier scaffold based on the antibiotic azithromycin, which greatly improved the compounds’ in vivo stability and uptake without negatively impacting their activity.
Find out more in the latest issue of ACS Pharmacology & Translational Science.